Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)

Completed · Phase 3

Conditions studied: Liver Disease

In brief

This study plans to learn more about a new test to look at liver function, the HepQuant-Shunt (HQ-Shunt). The HQ-Shunt is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient testing in patients with liver disease.

Key facts

Study ID

NCT02523196

Run by

University of Colorado, Denver

People needed

20

Starts

2016-03-01

Expected to finish

2017-02-23

Last updated by the study team

2021-08-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Liver disease patient scheduled to have an Hepatic Venous Pressure Gradient (HVPG) procedure
• At time of enrollment, being between the ages of 18 and 75

You may not qualify if…

• Concomitant treatment with both a beta blocker and an ACE inhibitor
• Concurrent hepatic malignancy. Patients with a history of treated HCC can be included if there is no evidence of recurrent disease at the time of this study.
• Unstable angina or history of myocardial infarction or congestive heart failure within 6 months prior to enrollment into this study
• Renal insufficiency with chronic kidney disease stage 4 or 5 (GFR < 30 mL/min/1.73m2)
• Crohn's disease or any active intestinal inflammatory condition
• Having had an ileal resection
• Diabetic Gastroparesis
• Pregnancy or intent to become pregnant. Urine pregnancy tests will be performed prior to HQ SHUNT testing.
• Inability to consent for one's self

Where it is running

• University of Colorado Denver (Leprino Building) — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.